Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3530 - Assessing Cancer Risk in Patients with HFE gene variants and Type 1 Hereditary Hemochromatosis.

Date

09 Sep 2017

Session

Poster display session

Presenters

Kimberley Youkhana

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

K. Youkhana1, V. Tutaeva1, H. Williams1, O. Corbali2, S. Krishnamurthy3, R. Metpally3, N. Kip1

Author affiliations

  • 1 Medical Oncology, Geisinger Medical Center, 17822 - Danville/US
  • 2 Faculty Of Medicine, Istanbul University, 17821 - Istanbul/TR
  • 3 Bioinformatics, Geisinger Medical Center, 17822 - Danville/US
More

Resources

Abstract 3530

Background

Patients with type 1 hereditary hemochromatosis are reported to have a 20-200-fold increased risk of hepatocellular carcinoma. However, not much is known about the risk of developing non-hepatobiliary cancers in these patients or those heterozygous for HFE variants. The purpose of this study is to assess the risk of non-hepatobiliary cancers in a large cohort.

Methods

Using the Geisinger-Regeneron DiscovEHR cohort, we sequenced whole exomes of 51,289 study participants to further analyze the HFE gene variations (C2892Y, H63D or S65C) for risk of cancer development. The cancer prevalence and statistical significance was assessed in both genders from multiple HFE genotypes.

Results

There were 51, 270 participants in this study: 30, 280 (59%) women and 20, 990 (41%) men. There was an increased risk of cancer overall among patients who harbored one or more HFE gene mutation (Kruskal-Wallis; p 

Conclusions

To our knowledge, this is the first whole exome sequencing study analyzing the HFE gene variants for cancer risk in over 50 thousand individuals. This study showed that cancer risk is increased in both HFE variants and non-HFE variants carriers and that cancer screening should be considered in this cohort.

Clinical trial identification

Legal entity responsible for the study

Geisinger Medical Center and Regeneron Pharmaceuticals

Funding

Regeneron Pharmaceuticals

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.